Virtual Group Speech Therapy for Head and Neck Cancer
Trial Summary
What is the purpose of this trial?
This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer. The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to consult with the trial coordinators or your healthcare provider for guidance.
What data supports the effectiveness of the treatment Virtual Group Speech Pathology Intervention for head and neck cancer?
The research indicates that speech pathology services, which include interventions like the Virtual Group Speech Pathology Intervention, can help improve speech and swallowing functions in patients after head and neck cancer treatment. This is supported by data showing optimal recovery of these functions at six months post-treatment, suggesting that such interventions can be beneficial.12345
Is virtual group speech therapy safe for head and neck cancer patients?
How is the Virtual Group Speech Pathology Intervention different from other treatments for head and neck cancer?
The Virtual Group Speech Pathology Intervention is unique because it uses a group setting to help patients practice and apply new speech techniques in a supportive environment, which may enhance the generalization of skills to everyday communication. Additionally, it is delivered virtually, improving access for patients who may face barriers to in-person therapy.1011121314
Eligibility Criteria
Adults over 18 with head or neck cancer starting chemoradiotherapy for cure can join. They need a radiation dose of at least 60 Grays and must speak French well enough for questionnaires. Those with distant cancer spread, planned total laryngectomy, prior severe swallowing issues, another simultaneous cancer, previous head/neck radiation, or significant cognitive impairments cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Chemoradiotherapy
Participants receive chemoradiotherapy treatment for head and neck cancer
Virtual Group Speech Therapy
Participants engage in a virtual, group-based speech therapy intervention guided by a patient partner
Follow-up
Participants are monitored for safety and effectiveness after treatment, including evaluation of nasogastric tube placement
Treatment Details
Interventions
- Virtual Group Speech Pathology Intervention
Virtual Group Speech Pathology Intervention is already approved in Canada for the following indications:
- Prevention of dysphagia in patients treated with chemoradiotherapy for head and neck cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Université du Québec à Trois-Rivières
Collaborator